CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
Introduction to PDABs: How US states are addressing high-cost prescription drugs
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.



